Marinomed appoints Cornelia Kutzer as CBO
Austrian drug developer Marinomed Biotech (VSE: MARI) today announced the appointment of Dr Cornelia Kutzer as chief business officer (CBO) of the company.
As CBO, Dr Kutzer will be responsible for further expanding Marinomed’s network of strategic partnerships both for product development and distribution in the therapeutic areas infectious diseases and immunology with an emphasis on ophthalmological indications.
“As we increase our efforts to realize the full potential of our product portfolio, we are delighted to now have such a successful and experienced management executive on board to optimize our business development activities,” Dr Andreas Grassauer, chief executive of Marinomed, said. “With her broad commercial expertise and impressive track record including high-value transactions, she will further advance Marinomed’s partnering strategy and will be an important part of our leadership team,” he noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze